At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
90Y-hLL2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG
In Brief
A Phase 2 clinical trial evaluating 90Y-hLL2 for NHL and 2 related conditions. Completed, enrolled 59 participants across 5 sites in 2 countries.
Detailed Summary
This will be an open label, multiple center, non-randomized, dose-escalation Phase I/II trial, designed to evaluate the safety and effectiveness of a repeated, outpatient regimen utilizing IMMU-hLL2 intact monoclonal antibody IgG labeled with different doses of 90Y for the treatment of patients B-cell lymphoma (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNHL, B-cell NHL, Non-Hodgkins Lymphoma
CountriesFrance, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2002
First PostedJan 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedJan 12, 2007
Enrollment StartAug 1, 2002
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 19.5 years ago
Interventions
90Y-hLL2biological
weekly dosing for either 2 or 3 weeks